Micrograph of a plasmacytoma, the histologic correlate of multiple myeloma. H&E stain. Credit: Wikipedia/CC BY-SA 3.0 The treatment landscape for multiple myeloma, the second most common blood cancer, is shifting rapidly, with newly diagnosed patients increasingly being treated with a four-part drug combination that includes a new immunotherapy agent. Over the last decade, options have evolved from double, to triple to quadruple combination therapies. What do these new options mean for patients, and how will treatment change in the future? C. Ola Landgren, M.D., Ph.D., will address these questions and Read More
No comments:
Post a Comment